Figure 2.

Crizotinib and cabozantinib inhibit HGF/Met-mediated PI3K and MAPK pathway activation. Cell types indicated were treated with (A) 5 nM or 10 nM of crizotinib (PF1066); or (B) 30 nM or 300 nM of cabozantinib (XL184) for 20 min, followed by concurrent 20 min treatment with HGF (1 nM); or (C) 10 nM crizotinib or 300 nM cabozantinib, as indicated. Cell lysates were then extracted with non-ionic detergent, separated by SDS-PAGE and immunoblotted for pAkt, Akt, pErk, or Erk as indicated.